摘要多发性骨髓瘤（MM）是血液系统第二大常见恶性肿瘤，标准的整体治疗模式及以新药为主的方案极大地改善了MM患者的生存，但微小残留病（MRD）导致大多数患者复发。因此，需要在传统血清学疗效评估的基础上联合MRD检测，以更精准地评估患者的疾病状态。目前，二代流式细胞术（NGF）和二代测序（NGS）是基于骨髓样本检测MRD的主流技术。为使MRD检测标准化和规范化，专家组讨论制订了在MM患者中应用NGF和NGS技术进行骨髓MRD检测的中国专家共识。

abstractsMultiple myeloma (MM) is the second most common hematologic malignant tumor. Standard holistic treatment model and new drug-based regimens have greatly improved the survival of patients with MM; however, minimal residual disease (MRD) causes relapse in most patients. Therefore, combining MRD testing on the basis of traditional serological efficacy evaluation is necessary to achieve a more accurate assessment of the patient's disease status. At present, next-generation flow cytometry (NGF) and next-generation sequencing (NGS) are the mainstream technologies for detecting MRD based on bone marrow samples. To standardize and normalize MRD detection, the expert group discussed and formulated Chinese expert consensus on the application of NGF and NGS technology for bone marrow MRD detection in patients with MM.